Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CHGCY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CHGCY and 80,000+ other tickers.
See exactly how CHGCY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CHGCY and 80,000+ other tickers.
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.
Chugai Pharmaceutical Co., Ltd. (CHGCY) Q1 2026 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call Transcript
Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q2 2025 Earnings Conference Call July 24, 2025 4:00 AM ET Company Participants a - Corporate Participant Iwaaki Taniguchi - Executive VP, Head of Finance Supervisory Division, CFO & Director Kae Miyata - Head of Corporate Communications Department Osamu Okuda - President, CEO & Chairman Tsukasa Kusano - Executive VP and Head of Project & Lifecycle Management Unit Conference Call Participants Akinori Ueda - Goldman Sachs Group, Inc., Research Division Fumiyoshi Sakai - UBS Investment Bank, Research Division Hidemaru Yamaguchi - Citigroup Inc., Research Division Kazuaki Hashiguchi - Daiwa Securities Co. Ltd.
Chugai Pharmaceutical Co. (CHGCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q4 2024 Earnings Conference Call January 30, 2025 3:30 AM ET Company Participants Kae Miyata - Head of Corporate Communications Department Osamu Okuda - Representative Director, President, and Chief Executive Officer Michiaki Tanaka - Head, R&D Portfolio Management Department, Project and Lifecycle Management Unit Iwaaki Taniguchi - Director, Executive Vice President, and Chief Financial Officer Takao Suzuki - Associate Vice President, Head of the Digital Transformation Unit Conference Call Participants Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - UBS Securities Seiji Wakao - JPMorgan Securities Hidemaru Yamaguchi - Citigroup Global Markets Stephen Barker - Jefferies Tony Ren - Macquarie Capital Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Miki Sogi - AllianceBernstein Japan Kae Miyata Ladies and gentlemen, thank you for attending the conference on FY 2024 December financial results for Chugai Pharmaceutical.